New Products In Brief
Perrigo generic Nicorette approval: The Allegan, Mich.-based generics manufacturer has received FDA approval to market store-brand versions of GlaxoSmithKline's Nicorette Fresh Mint (coated nicotine polacrilex gum 2 mg and 4 mg) smoking cessation gum, the firm announces June 14. Retail sales for GSK's Fresh Mint gum were approximately $100 mil. for the past 12 months. Perrigo currently produces generic versions of GSK's uncoated NRT gum products as well as nicotine polacrilex lozenges equivalent to GSK's Commit product. "We are pleased with this important addition to our store brand nicotine replacement therapy product offerings, even though some sales may come at the expense of our uncoated gum products," Executive VP and General Manager - Perrigo Consumer Healthcare John Hendrickson states. The product will begin shipping to food, drug, mass market, dollar store and club store retailers in the fourth quarter and will cost approximately 25% to 40% less than the branded, the firm says...
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
New plan to encourage alternatives to animal testing seeks interagency cooperation to meet more aggressive targets for transformational change than the US FDA’s long-standing program.
HHS Secretary Robert F. Kennedy Jr. urged FDA staff to resist the “deep state” and “crony capitalism,” and focus on improving the health of America’s children. “You're not here to take orders,” he said and urged FDA staff to speak up if they see wrongdoing.
Antabio’s next-generation, broad-spectrum antibacterial, MEM-ANT3310, has made it onto the European Medicines Agency’s priority medicines scheme. The company says its product is designed to make a significant impact on the growing problem of antimicrobial resistance.